港股異動 | 環亞國際實業漲逾41% 獲伯傑醫療獨家代理於歐洲五國銷售新冠病毒試劑盒
格隆匯3月18日丨環亞國際實業(1143.HK)早盤一度大漲逾1.5倍,現漲幅收窄至41.82%,報0.078港元,暫成交1268萬港元,最新總市值5.6億港元。環亞國際實業昨日盤後公佈,於3月16日,公司與上海伯傑醫療簽署獨家代理協議,自簽訂之日起至2020年6月15日,伯傑醫療授予公司在歐洲五國包括意大利、德國、西班牙、法國和英國獨家代理銷售,及其它國家非獨家代理銷售其新冠病毒(COVID-19)檢測試劑盒相關產品。據悉,伯傑醫療是一家致力於感染性病原體分子診斷試劑研發和應用、深耕於多重熒光PCR診斷試劑的高新技術企業。目前,伯傑醫療申請專利23項,3款產品拿到了國家藥品監督管理局的註冊證和生產許可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.